Notices. Notice
244 words·~1 min read·
/register/2001/11/06/01-27866·A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
BILLING CODE 3710-08-M DEPARTMENT OF DEFENSE Department of the Army Availability for Non-Exclusive, Exclusive, or Partially Exclusive Licensing of U.S. Patent Application Concerning Treatment of and/or Prophylaxis Against Brain and Spinal Cord Injury AGENCY: Army Medical Research and Materiel Command, DOD. ACTION: Notice. SUMMARY: In accordance with 37 CFR 404.6, announcement is made of the availability for licensing of U.S. Patent Application No. 09/556,954 entitled “Treatment of and/or Prophylaxis Against Brain and Spinal Cord Injury” and filed April 21, 2000.
The United States Government, as represented by the Secretary of the Army, has rights in this invention. ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command, ATTN: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort Detrick, Frederick, Maryland 21702-5012. FOR FURTHER INFORMATION CONTACT: For patent issues, Ms. Elizabeth Arwine, Patent Attorney,
(301)619-7808. For licensing issues, Dr. Paul Mele, Office of Research & Technology Assessment,
(301)619-6664. Both at telefax
(301)619-5034. SUPPLEMENTARY INFORMATION: The administration of α-lipoic acid (α-LA) and dihydrolipoic acid
(DHL)both as a preventive measure before exposure to conditions which may cause damage, such as rapid changes in atmospheric pressure, and as a means of preventing or ameliorating damage arising from such injury provides benefits not currently available. The active agents may be administered systematically or to the injured tissue. For example, when there is spinal cord injury, the active agents may be administered intrathecally. Luz D. Ortiz, Army Federal Register Liaison Officer. [FR Doc. 01-27866 Filed 11-5-01; 8:45 am]
Connectionstraces to 1
Traces to 1 document